Latest Japan Approvals Include Evrysdi For SMA

Plus Global First For Imeglimin

Japan's latest batch of product approvals includes the country's second therapy for SMA and the first nod globally for a novel antidiabetic.

migraine
Two New Migraine Drugs Approved In Japan • Source: Alamy

Chugai Pharmaceutical Co., Ltd.’s Evrysdi (risdiplam) is among the latest batch of new drug approvals in Japan, providing another option for spinal muscular atrophy (SMA) patients in the country. The survival motor neuron 2 (SMN2)-directed splicing modifier was granted orphan designation in March 2019 and filed for approval last October.

Attention is now turning to how the therapy will be priced under the national health insurance system, which will enable...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Japan

More from Asia